Disease · MONDO_0024574
von Willebrand disease (hereditary or acquired)
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. von Willebrand disease (hereditary or acquired). Diseases, record MONDO_0024574. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0024574
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- VWD, Von Willebrand Disease, von Willebrand disorder, von Willebrand's disease
- Open Targets
Drugs10
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| VONICOG ALFA | CHEMBL2107873 | Protein | Approval | PMDA | 2 | 1 | 1 | Drugs and targets |
| DESMOPRESSIN ACETATE | CHEMBL1200556 | Protein | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| VON WILLEBRAND FACTOR HUMAN | CHEMBL4298126 | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets | |
| ANTIHEMOPHILIC FACTOR, PEGYLATED (MW 20000) HUMAN SEQUENCE RECOMBINANT | CHEMBL4594584 | Phase 3 | ClinicalTrials.gov | 2 | 2 | 0 | Drugs and targets | |
| EFMOROCTOCOG ALFA | CHEMBL4297945 | Protein | Phase 3 | ClinicalTrials.gov | 2 | 2 | 0 | Drugs and targets |
| HUMAN COAGULATION FACTOR VIII | CHEMBL2108175 | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets | |
| LONOCTOCOG ALFA | CHEMBL4594603 | Protein | Phase 3 | ClinicalTrials.gov | 2 | 2 | 0 | Drugs and targets |
| MOROCTOCOG ALFA | CHEMBL2109137 | Protein | Phase 3 | ClinicalTrials.gov | 2 | 2 | 0 | Drugs and targets |
| OCTOCOG ALFA | CHEMBL4297873 | Protein | Phase 3 | ClinicalTrials.gov | 2 | 2 | 0 | Drugs and targets |
| OPRELVEKIN | CHEMBL1201573 | Protein | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
Targets6
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| F8 | Coagulation factor VIII | 6 | Coagulation factor VIII exogenous protein | Phase 3 | https://conductscience.org/library/genes/2157 | Drugs and targets |
| VWF | von Willebrand factor | 2 | von Willebrand factor exogenous protein | Approval | https://conductscience.org/library/genes/7450 | Drugs and targets |
| AVPR1A | Vasopressin receptor | 1 | Vasopressin receptor agonist | Approval | https://conductscience.org/library/genes/552 | Drugs and targets |
| AVPR1B | Vasopressin receptor | 1 | Vasopressin receptor agonist | Approval | https://conductscience.org/library/genes/553 | Drugs and targets |
| AVPR2 | Vasopressin receptor | 1 | Vasopressin receptor agonist | Approval | https://conductscience.org/library/genes/554 | Drugs and targets |
| IL11RA | Interleukin-11 receptor subunit alpha | 1 | Interleukin 11 receptor alpha agonist | Phase 2 | https://conductscience.org/library/genes/3590 | Drugs and targets |
Trials8
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01410227 | Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD) | Phase 3 | 49 | 2016-04-21 | Von Willebrand Disease | VON WILLEBRAND FACTOR HUMAN | Its record names the disease | ClinicalTrials.gov |
| NCT02283268 | Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery | Phase 3 | 24 | 2017-08-31 | Von Willebrand Disease | VON WILLEBRAND FACTOR HUMAN | Its record names the disease | ClinicalTrials.gov |
| NCT04953884 | Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age | Phase 3 | 12 | 2026-02-20 | Von Willebrand Disease | HUMAN COAGULATION FACTOR VIII, VON WILLEBRAND FACTOR HUMAN | Its record names the disease | ClinicalTrials.gov |
| NCT00994929 | Efficacy and Safety of IL-11 in DDAVP Unresponsive | Phase 2 | 9 | 2016-03-02 | Hemophilia A, Von Willebrand Disease | OPRELVEKIN | Its record names the disease | ClinicalTrials.gov |
| NCT00524342 | IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia | Phase 2 | 7 | 2014-11-07 | Von Willebrand Disease | OPRELVEKIN | Its record names the disease | ClinicalTrials.gov |
| NCT00524225 | IL-11 in Adults With Von Willebrand Disease Undergoing Surgery | Phase 2 | 3 | 2014-11-07 | Von Willebrand Disease | OPRELVEKIN | Its record names the disease | ClinicalTrials.gov |
| NCT02932618 | A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD) | Phase 3 | 47 | Von Willebrand Disease | HUMAN COAGULATION FACTOR VIII, VONICOG ALFA | Its record names the disease | ClinicalTrials.gov | |
| NCT00816660 | Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease | Phase 1 | 32 | Von Willebrand Disease | VON WILLEBRAND FACTOR HUMAN | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials4
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0024574
GET https://conductscience.org/api/diseases/v1/MONDO_0024574/drugs